case_images: PMC11390346_01
case_images: Treatment response was evaluated by chest CT imaging after lorlatinib. Representative CT images obtained with the lung window (upper row) and mediastinal window (lower row). Red circle indicates the location of the tumor on the lower lobe of the right lung. Line chart demonstrate the change of tumor long diameter (mm).
case_images: fonc-14-1415254-g001.jpg
case_images: PMC11390346_01_fonc-14-1415254-g001.jpg
case_images: f1
case_images: Chest computed tomography (CT) ( Figure 1 ) showed the wall of the middle segment bronchus, middle lobe and lower lobe bronchus of the right lung was thickened, with stenosis and local truncation of the lumen. The response was evaluated by chest CT imaging at 1, 6 and 14 months after lorlatinib, showing that the tumor volume was reduced ( Figure 1 ).
case_images: Pathological analyses: hematoxylin and eosin (H&E) staining and immunohistochemical (IHC) analyses (representative IHC results of NapsinA, p63, TTF-1, Ki-67).
case_images: fonc-14-1415254-g002.jpg
case_images: PMC11390346_01_fonc-14-1415254-g002.jpg
case_images: f2
case_images: The results of immunohistochemical (IHC) staining ( Figure 2 ) were suggestive of high-grade MEC.
case_images: Integrative genome visualization(IGV) of the mutant gene sequence, showing the identification of EML4-ALK.
case_images: fonc-14-1415254-g003.jpg
case_images: PMC11390346_01_fonc-14-1415254-g003.jpg
case_images: f3
case_images: Further detection of next generation sequencing (NGS) revealed EML4-ALK fusion variants E20:A20 (V2) ( Figure 3 ).